| Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF[V600E]-associated thyroid carcinoma. | Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF(V600E)-associated thyroid carcinoma.
Zhang P, Guan L, Sun W, Zhang Y, Du Y, Yuan S, Cao X, Yu Z, Jia Q, Zheng X, Meng Z, Li X, Zhao L., Free PMC Article | 05/30/2024 |
| Exploring the role of sporadic BRAF and KRAS mutations during colorectal cancer pathogenesis: A spotlight on the contribution of the endosome-lysosome system. | Exploring the role of sporadic BRAF and KRAS mutations during colorectal cancer pathogenesis: A spotlight on the contribution of the endosome-lysosome system.
Tang J, Lam GT, Brooks RD, Miles M, Useckaite Z, Johnson IR, Ung BS, Martini C, Karageorgos L, Hickey SM, Selemidis S, Hopkins AM, Rowland A, Vather R, O'Leary JJ, Brooks DA, Caruso MC, Logan JM. | 03/5/2024 |
| HSPA8 Activates Wnt/beta-Catenin Signaling to Facilitate BRAF V600E Colorectal Cancer Progression by CMA-Mediated CAV1 Degradation. | HSPA8 Activates Wnt/β-Catenin Signaling to Facilitate BRAF V600E Colorectal Cancer Progression by CMA-Mediated CAV1 Degradation.
Li B, Ming H, Qin S, Zhou L, Huang Z, Jin P, Peng L, Luo M, Zhang T, Wang K, Liu R, Liou YC, Nice EC, Jiang J, Huang C., Free PMC Article | 02/1/2024 |
| Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids. | Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids.
Lasolle H, Schiavo A, Tourneur A, Gillotay P, de Faria da Fonseca B, Ceolin L, Monestier O, Aganahi B, Chomette L, Kizys MML, Haenebalcke L, Pieters T, Goossens S, Haigh J, Detours V, Maia ALS, Costagliola S, Romitti M., Free PMC Article | 01/27/2024 |
| Telomere dysfunction in Tert knockout mice delays Braf[V600E] -induced melanoma development. | Telomere dysfunction in Tert knockout mice delays Braf(V600E) -induced melanoma development.
Zhang J, Zhang F, Porter KI, Dakup PP, Wang S, Robertson GP, Gaddameedhi S, Zhu J., | 01/4/2024 |
| BRAF D594A mutation defines a unique biological and immuno-modulatory subgroup associated with functional CD8[+] T cell infiltration in colorectal cancer. | BRAF D594A mutation defines a unique biological and immuno-modulatory subgroup associated with functional CD8(+) T cell infiltration in colorectal cancer.
Li W, Zhao C, Li W, Gong Y, Ma K, Lu Y, Liu X, Zhang L, Guo F., Free PMC Article | 10/30/2023 |
| STAG2 inactivation reprograms glutamine metabolism of BRAF-mutant thyroid cancer cells. | STAG2 inactivation reprograms glutamine metabolism of BRAF-mutant thyroid cancer cells.
Li X, Liu Y, Liu J, Qiang W, Ma J, Xie J, Chen P, Wang Y, Hou P, Ji M., Free PMC Article | 10/26/2023 |
| BRAF[V600E]-mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism. | BRAF(V600E)-mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism.
Rzasa P, Whelan S, Farahmand P, Cai H, Guterman I, Palacios-Gallego R, Undru SS, Sandford L, Green C, Andreadi C, Mintseva M, Parrott E, Jin H, Hey F, Giblett S, Sylvius NB, Allcock NS, Straatman-Iwanowska A, Feuda R, Tufarelli C, Brown K, Pritchard C, Rufini A., Free PMC Article | 09/27/2023 |
| BRAF(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes. | BRAF(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes.
Yap J, Yuan J, Ng WH, Chen GB, Sim YRM, Goh KC, Teo J, Lim TYH, Goay SM, Teo JHJ, Lao Z, Lam P, Sabapathy K, Hu J., Free PMC Article | 08/7/2023 |
| S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas. | S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas.
Mehdi A, Attias M, Arakelian A, Szyf M, Piccirillo CA, Rabbani SA., Free PMC Article | 02/4/2023 |
| Central role for BRAF in cardiac hypertrophy: rethinking the pathological-physiological divide. | Central role for BRAF in cardiac hypertrophy: rethinking the pathological-physiological divide.
Altara R, Booz GW., Free PMC Article | 01/28/2023 |
| Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice. | Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice.
Alharbi HO, Hardyman MA, Cull JJ, Markou T, Cooper STE, Glennon PE, Fuller SJ, Sugden PH, Clerk A., Free PMC Article | 12/3/2022 |
| Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. | Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis.
Vaishnavi A, Juan J, Jacob M, Stehn C, Gardner EE, Scherzer MT, Schuman S, Van Veen JE, Murphy B, Hackett CS, Dupuy AJ, Chmura SA, van der Weyden L, Newberg JY, Liu A, Mann K, Rust AG, Weiss WA, Kinsey CG, Adams DJ, Grossmann A, Mann MB, McMahon M., Free PMC Article | 11/26/2022 |
| AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis. | AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis.
Kim H, Jeong M, Na DH, Ryu SH, Jeong EI, Jung K, Kang J, Lee HJ, Sim T, Yu DY, Yu HC, Cho BH, Jung YK., Free PMC Article | 06/11/2022 |
| Early differential responses elicited by BRAF(V600E) in adult mouse models. | Early differential responses elicited by BRAF(V600E) in adult mouse models.
Bosso G, Lanuza-Gracia P, Piñeiro-Hermida S, Yilmaz M, Serrano R, Blasco MA., Free PMC Article | 04/16/2022 |
| Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo. | Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo.
Clerk A, Meijles DN, Hardyman MA, Fuller SJ, Chothani SP, Cull JJ, Cooper STE, Alharbi HO, Vanezis K, Felkin LE, Markou T, Leonard SJ, Shaw SW, Rackham OJL, Cook SA, Glennon PE, Sheppard MN, Sembrat JC, Rojas M, McTiernan CF, Barton PJ, Sugden PH., Free PMC Article | 03/5/2022 |
| SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis. | SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis.
Tong K, Kothari OA, Haro KS, Panda A, Bandari MM, Carrick JN, Hur JJ, Zhang L, Chan CS, Xing J, Gatza ML, Ganesan S, Verzi MP., Free PMC Article | 01/29/2022 |
| BRAF(V600E) Overrides NOTCH Signaling in Thyroid Cancer. | BRAF(V600E) Overrides NOTCH Signaling in Thyroid Cancer.
Traversi F, Stooss A, Dettmer MS, Charles RP. | 01/22/2022 |
| Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. | Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett DR, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM., Free PMC Article | 01/8/2022 |
| Targeting a Braf/Mapk pathway rescues podocyte lipid peroxidation in CoQ-deficiency kidney disease. | Targeting a Braf/Mapk pathway rescues podocyte lipid peroxidation in CoQ-deficiency kidney disease.
Sidhom EH, Kim C, Kost-Alimova M, Ting MT, Keller K, Avila-Pacheco J, Watts AJ, Vernon KA, Marshall JL, Reyes-Bricio E, Racette M, Wieder N, Kleiner G, Grinkevich EJ, Chen F, Weins A, Clish CB, Shaw JL, Quinzii CM, Greka A., Free PMC Article | 09/25/2021 |
| BRAFV600E expression in neural progenitors results in a hyperexcitable phenotype in neocortical pyramidal neurons. | BRAFV600E expression in neural progenitors results in a hyperexcitable phenotype in neocortical pyramidal neurons.
Goz RU, Akgül G, LoTurco JJ., Free PMC Article | 07/24/2021 |
| BRAF(V600E)-induced senescence drives Langerhans cell histiocytosis pathophysiology. | BRAF(V600E)-induced senescence drives Langerhans cell histiocytosis pathophysiology.
Bigenwald C, Le Berichel J, Wilk CM, Chakraborty R, Chen ST, Tabachnikova A, Mancusi R, Abhyankar H, Casanova-Acebes M, Laface I, Akturk G, Jobson J, Karoulia Z, Martin JC, Grout J, Rafiei A, Lin H, Manz MG, Baccarini A, Poulikakos PI, Brown BD, Gnjatic S, Lujambio A, McClain KL, Picarsic J, Allen CE, Merad M., Free PMC Article | 06/26/2021 |
| Oncogenic BRAF, unrestrained by TGFbeta-receptor signalling, drives right-sided colonic tumorigenesis. | Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis.
Leach JDG, Vlahov N, Tsantoulis P, Ridgway RA, Flanagan DJ, Gilroy K, Sphyris N, Vázquez EG, Vincent DF, Faller WJ, Hodder MC, Raven A, Fey S, Najumudeen AK, Strathdee D, Nixon C, Hughes M, Clark W, Shaw R, S:CORT consortium, van Hooff SR, Huels DJ, Medema JP, Barry ST, Frame MC, Unciti-Broceta A, Leedham SJ, Inman GJ, Jackstadt R, Thompson BJ, Campbell AD, Tejpar S, Sansom OJ., Free PMC Article | 06/19/2021 |
| Alterations in signaling pathways that accompany spontaneous transition to malignancy in a mouse model of BRAF mutant microsatellite stable colorectal cancer. | Alterations in signaling pathways that accompany spontaneous transition to malignancy in a mouse model of BRAF mutant microsatellite stable colorectal cancer.
Kane AM, Fennell LJ, Liu C, Borowsky J, McKeone DM, Bond CE, Kazakoff S, Patch AM, Koufariotis LT, Pearson J, Waddell N, Leggett BA, Whitehall VLJ., Free PMC Article | 05/29/2021 |
| Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans. | Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans.
Gualtieri A, Kyprianou N, Gregory LC, Vignola ML, Nicholson JG, Tan R, Inoue SI, Scagliotti V, Casado P, Blackburn J, Abollo-Jimenez F, Marinelli E, Besser REJ, Högler W, Karen Temple I, Davies JH, Gagunashvili A, Robinson ICAF, Camper SA, Davis SW, Cutillas PR, Gevers EF, Aoki Y, Dattani MT, Gaston-Massuet C., Free PMC Article | 04/24/2021 |